Femasys INC 10-Q quarterly reports

Femasys reports Q1 2026 net income of $0.85 million, driven by non-cash gains, while maintaining a going concern warning due to liquidity constraints.

Femasys Inc. reported a 31.4% increase in Q3 2025 sales, driven by FemBloc, but saw net losses widen for the nine-month period and faces ongoing liquidity and Nasdaq compliance challenges.

Femasys Inc. reports increased sales and product approvals but warns of substantial doubt about its ability to continue as a going concern, facing Nasdaq delisting and urgent capital needs.

Femasys Inc. announces its financial results for the first quarter of 2025, highlighting increased sales and ongoing development of its FemBloc permanent birth control system.

Femasys Inc. saw a significant increase in sales and continued progress in the commercialization of its products during the third quarter of 2024, while also advancing its clinical programs.

Femasys Inc. reported a net loss of $4.68 million for the second quarter of 2024, while progressing with the commercial launch of FemaSeed and the clinical trial for FemBloc.

Femasys Inc. reported a net loss of $3.6 million for the first quarter of 2024, while making progress in the commercialization of FemaSeed and the clinical trial of FemBloc.